Welcome to our dedicated page for Axon Enterprise SEC filings (Ticker: AXON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axon Enterprise, Inc. filings document operating results and corporate actions for a public safety technology company with Software & Services and Connected Devices activities. Form 8-K reports include shareholder letters on financial results and outlooks, product demand across TASER devices, Axon Body cameras, Axon Evidence, AI products, counter-drone offerings and real-time operations, as well as material-event disclosures tied to capital structure.
Proxy materials cover board composition, shareholder meeting matters, executive compensation and equity awards. Other 8-K and 8-K/A filings record director election updates and the redemption and settlement of 0.50% convertible senior notes due 2027, including the disclosure that no convertible notes remained outstanding after the redemptions and conversions.
Axon Enterprise, Inc. (AXON) – Form 4 insider transaction summary: President Joshua Isner reported two transactions involving AXON common stock. On 16-Jun-2025, 680 shares were disposed under transaction code F (shares withheld to cover income-tax obligations triggered by restricted stock unit (RSU) vesting) at a price of $780.63 per share. On 17-Jun-2025, Isner sold 905 shares in the open market at $776.39 per share under a pre-arranged Rule 10b5-1 trading plan adopted on 21-Aug-2024.
Following these actions, Isner’s direct beneficial ownership declined from 270,320 shares to 268,735 shares, a reduction of roughly 0.6 % of his total position and an immaterial fraction of Axon’s ~74 million shares outstanding. No derivative securities were involved and no new options were granted or exercised. The filing indicates routine tax withholding and modest portfolio diversification rather than a strategic divestiture. Because the sales were both limited in size and executed under a 10b5-1 plan, the market impact is expected to be neutral to modestly negative.